Literature DB >> 2368445

Epidermal growth factor receptors and adenylate cyclase activity in human thyroid tissues.

Q Y Duh1, A E Siperstein, R A Miller, J J Sancho, M J Demeure, O H Clark.   

Abstract

Thyroid stimulating hormone (TSH) and epidermal growth factor (EGF) are growth factors for some thyroid cells in cultures. We have previously found more EGF receptors in neoplastic human thyroid tissues than in normal thyroid tissues. We have also found a higher TSH-stimulated adenylate cyclase (AC) activity in neoplastic human thyroid tissues than in normal thyroid tissues. To clarify the relationship between the effect of EGF and TSH on thyroid tissue, we measured the binding of EGF and TSH and the basal, TSH-stimulated and forskolin-stimulated adenylate cyclase activity in 49 normal, hyperplastic and neoplastic human thyroid tissues (5 normal, 2 Hashimoto thyroiditis, 5 Graves' disease, 14 multinodular goiters, 9 follicular adenomas, 5 follicular carcinomas, 8 papillary carcinomas, and 1 undifferentiated carcinoma). Specific binding of EGF and TSH were measured by radioreceptor assays using competitive inhibition of radio-labeled ligand by unlabeled ligand. Basal, maximally (300 mU/ml) TSH-stimulated, and maximally (100 mM) forskolin-stimulated adenylate cyclase activities were also measured in the same membrane particulate fractions from the thyroid tissues. We found: neoplastic thyroid tissues bind more labeled EGF than nonneoplastic thyroid tissues; follicular adenomas and carcinomas have higher EGF binding than other thyroid tissues; a weak but significant correlation between specific EGF binding and specific TSH binding, and between specific EGF binding and TSH-stimulated adenylate cyclase activity of the thyroid membrane preparations. These findings are consistent with the hypothesis that TSH stimulates an increase in thyroid EGF receptors by increasing intracellular cAMP.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2368445     DOI: 10.1007/bf01658542

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  41 in total

1.  Improved medium for clonal growth of human diploid fibroblasts at low concentrations of serum protein.

Authors:  W L McKeehan; K A McKeehan; S L Hammond; R G Ham
Journal:  In Vitro       Date:  1977-07

2.  Epidermal growth factor receptors in plasma membranes of normal and diseased human thyroid glands.

Authors:  A Kanamori; Y Abe; Y Yajima; Y Manabe; K Ito
Journal:  J Clin Endocrinol Metab       Date:  1989-05       Impact factor: 5.958

3.  Adenylate cyclase activity as a predictor of thyroid tumor aggressiveness.

Authors:  A E Siperstein; Q H Zeng; E T Gum; K E Levin; O H Clark
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

4.  Effects of thyroxine on cell proliferation in human multinodular goiter: a study on growth of thyroid tissue transplanted to nude mice.

Authors:  S Smeds; H J Peter; H Gerber; E Jörtsö; S Lennquist; H Studer
Journal:  World J Surg       Date:  1988-04       Impact factor: 3.352

5.  Biological characteristics of adenomatous nodules, adenomas, and hyperfunctioning nodules as defined by adenylate cyclase activity and TSH receptors.

Authors:  C G Thomas; W Combest; R McQuade; H Jordan; R Reddick; S N Nayfeh
Journal:  World J Surg       Date:  1984-08       Impact factor: 3.352

6.  Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers.

Authors:  M C Hollstein; A M Smits; C Galiana; H Yamasaki; J L Bos; A Mandard; C Partensky; R Montesano
Journal:  Cancer Res       Date:  1988-09-15       Impact factor: 12.701

7.  Estrogen and thyroid-stimulating hormone (TSH) receptors in neoplastic and nonneoplastic human thyroid tissue.

Authors:  O H Clark; P L Gerend; M Davis; P E Goretzki; P G Hoffman
Journal:  J Surg Res       Date:  1985-02       Impact factor: 2.192

8.  Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours.

Authors:  D E Neal; C Marsh; M K Bennett; P D Abel; R R Hall; J R Sainsbury; A L Harris
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

9.  Thyrotropin binding and adenylate cyclase activation in normal and neoplastic human thyroid tissue: lack of effect of thyroglobulin.

Authors:  O H Clark; P L Gerend; R A Nissenson
Journal:  J Clin Endocrinol Metab       Date:  1982-06       Impact factor: 5.958

10.  Thyroid cell responses to thyrotropin and 12-O-tetradecanoyl-phorbol-13-acetate: translocation of protein kinase C and phosphorylation of thyroid cell polypeptide substrates.

Authors:  A Tanabe; T B Nielsen; C S Rani; J B Field
Journal:  Arch Biochem Biophys       Date:  1985-11-15       Impact factor: 4.013

View more
  6 in total

1.  Expression of the estrogen receptor α, progesterone receptor and epidermal growth factor receptor in papillary thyroid carcinoma tissues.

Authors:  Dan Chen; Wenjing Qi; Pengxin Zhang; Hongwei Guan; Lifen Wang
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

2.  Aberrations of growth factor control in metastatic follicular thyroid cancer in vitro.

Authors:  T Hoelting; A Zielke; A E Siperstein; O H Clark; Q Y Duh
Journal:  Clin Exp Metastasis       Date:  1994-07       Impact factor: 5.150

3.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

4.  Expression of PACAP and PAC1 Receptor in Normal Human Thyroid Gland and in Thyroid Papillary Carcinoma.

Authors:  Sebastian Bardosi; Attila Bardosi; Zsuzsanna Nagy; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2016-08-26       Impact factor: 3.444

5.  Increased binding capacity of receptors for the epidermal growth factor in benign thyroid nodules and thyroid malignancies.

Authors:  B Saller; G Stapfer; B Bein; R Hoermann; F Spelsberg; K Mann
Journal:  Clin Investig       Date:  1993-11

6.  Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.

Authors:  S Hoffmann; S Gläser; A Wunderlich; S Lingelbach; C Dietrich; A Burchert; H Müller; M Rothmund; A Zielke
Journal:  Langenbecks Arch Surg       Date:  2006-10-12       Impact factor: 3.445

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.